Quest Diagnostics Innovates Alzheimer's Detection with AD-Detect® Blood Tests
- Quest Diagnostics has developed two blood tests, AD-Detect®, for early Alzheimer's disease diagnosis, aiming to reduce reliance on traditional methods.
- The tests show high accuracy with sensitivity and specificity rates of 91%, aligning with leading Alzheimer's diagnostic standards.
- Quest Diagnostics is committed to improving Alzheimer's diagnostics through innovative blood-based testing, enhancing patient care and timely interventions.
Quest Diagnostics Advances Alzheimer's Diagnostics with Innovative Blood Tests
Quest Diagnostics has made significant strides in the early diagnosis of Alzheimer's disease through the development of two blood-based tests known as AD-Detect®. Recently published findings in Neurology® Clinical Practice underscore the tests' high accuracy, suggesting they could substantially decrease the reliance on traditional diagnostic methods such as PET imaging and cerebrospinal fluid testing. Conducted in collaboration with the 1Florida Alzheimer’s Disease Research Center at the University of Florida, the study highlights the potential for these tests to streamline the diagnostic process for patients exhibiting symptoms of mild cognitive impairment or Alzheimer's disease.
The first of the AD-Detect® tests targets key biomarkers: amyloid beta (AB) 42/40, phosphorylated tau (p-tau) 217, and the ApoE4 proteotype, with an expected launch in the first quarter of 2026. The second test, which omits the ApoE4 component, is already available, having launched in April 2025 as the AD-Detect™ ABeta 42/40 and p-tau217 Evaluation panel. Both tests demonstrate impressive sensitivity and specificity rates of 91%, aligning with the Alzheimer's Association and Global CEO Initiative on Alzheimer's Disease standards for confirmatory testing, which call for around 90% accuracy. This level of precision is crucial for enhancing clinical decision-making, as noted by Dr. Michael Racke, Senior Medical Director of Neurology at Quest Diagnostics, who points out the potential for an indeterminate result rate as low as 10%.
The implications of these advancements are profound for the healthcare landscape. With a study sample of 215 patients, nearly half of whom were amyloid PET-positive, the results affirm the tests' effectiveness in the intended-use population. As clinical guidelines evolve, the integration of blood-based diagnostics like AD-Detect® could redefine Alzheimer's testing protocols, making it more accessible and less invasive for patients. This aligns with the growing need for efficient diagnostic tools in a field that has traditionally relied on more complex and costly procedures.
In addition to these diagnostic innovations, Quest Diagnostics remains committed to enhancing patient care through research and collaboration. The company's ongoing efforts aim to address the increasing demand for reliable Alzheimer's disease diagnostics, which is pivotal as the population ages and the prevalence of cognitive disorders rises. By focusing on blood-based testing, Quest aims to not only improve diagnostic accuracy but also to provide healthcare providers with reliable tools that can facilitate timely interventions for patients.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

